Bioethics News

More Trouble for Theranos: Company Halts Zika Test After FDA Inspection

September 1, 2016

(Managed Care Magazine) – Theranos Inc. has withdrawn its request for emergency clearance of a Zika virus blood test after the FDA found that the company didn’t include proper patient safeguards in a study of the new test, according to a report in the Wall Street Journal. The move is another black eye for the California-based company, which is still reeling under heavy sanctions imposed on it because of deficiencies in its technology and operations.

The views, opinions and positions expressed by these authors and blogs are theirs and do not necessarily represent that of the Bioethics Research Library and Kennedy Institute of Ethics or Georgetown University.